Related references
Note: Only part of the references are listed.A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma
Emilie M. J. van Brummelen et al.
INVESTIGATIONAL NEW DRUGS (2020)
Intracavitary cisplatin-fibrin chemotherapy after surgery for malignant pleural mesothelioma: A phase I trial
Isabelle Opitz et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2020)
Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial
Neil Bayman et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study
Dean A. Fennell et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The combined treatment of 150 kHz tumor treating fields (TTFields) and sorafenib inhibits hepatocellular carcinoma in vitro and in vivo.
Uri Weinberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent.
Prasad S. Adusumilli et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Return to intended oncologic treatment after surgery for malignant pleural mesothelioma
David B. Nelson et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2019)
Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy
Raffit Hassan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial
Giorgio V. Scagliotti et al.
LANCET RESPIRATORY MEDICINE (2019)
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
Michele Carbone et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma
Raffit Hassan et al.
CLINICAL CANCER RESEARCH (2019)
Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)
Morihito Okada et al.
CLINICAL CANCER RESEARCH (2019)
A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial
Robert A. Belderbos et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naive Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905)
Anne S. Tsao et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
LBA91_PRA multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
S Popat et al.
ANNALS OF ONCOLOGY (2019)
1226PA phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells
A Curioni et al.
ANNALS OF ONCOLOGY (2019)
BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment
Alice Guazzelli et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma
Neelam Kumar et al.
LUNG CANCER (2019)
Immunotherapy strategies for mesothelioma - the role of tumor specific neoantigens in a new era of precision medicine
Linda Ye et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2019)
A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy
Prasad S. Adusumilli et al.
CANCER RESEARCH (2019)
Mesothelin as a biomarker for targeted therapy
Jiang Lv et al.
BIOMARKER RESEARCH (2019)
NF2/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma
Tatsuhiro Sato et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline
Hedy L. Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
CONFIRM: a double-blind, placebo controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial
Dean A. Fennell et al.
TRIALS (2018)
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study
Luana Calabro et al.
LANCET RESPIRATORY MEDICINE (2018)
Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.
Marjorie Glass Zauderer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma
Yannis Metaxas et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
A Phase I/II Study of Intrapleural Ad-SGE-REIC Administration in Patients with Refractory Malignant Pleural Mesothelioma
Y. Goto et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
STELLAR - Final Results of a Phase 2 Trial of TTFields with Chemotherapy for First-Line Treatment of Malignant Pleural Mesothelioma
G. Ceresoli et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Phase II Trial of Pembrolizumab (NCT02399371) In Previously-Treated Malignant Mesothelioma (MM): Final Analysis
A. Desai et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response
Jingli Zhang et al.
CLINICAL CANCER RESEARCH (2017)
Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.
Arnaud Scherpereel et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers
Emma Beddowes et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial
Federica Grosso et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905)
Anne S. Tsao et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Prospective ImmunogenomiC PrOfiling of Non-Small Cell Lung Cancer - The ICON Project
Boris Sepesi et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
A Phase II Study of Nivolumab in Malignant Pleural Mesothelioma (NivoMes): with Translational Research (TR) Biopies
Josine Quispel-Janssen et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma
H. L. Kindler et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
Michele Maio et al.
LANCET ONCOLOGY (2017)
Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study
Nico van Zandwijk et al.
LANCET ONCOLOGY (2017)
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
Evan W. Alley et al.
LANCET ONCOLOGY (2017)
A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group
Scott A. Laurie et al.
LUNG CANCER (2017)
BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation
Angela Bononi et al.
NATURE (2017)
IN-DEPTH REVIEW: CHIMERIC ANTIGEN RECEPTOR T CELLS-BASED THERAPIES CAR T-cell therapy for lung cancer and malignant pleural mesothelioma
Masha Zeltsman et al.
TRANSLATIONAL RESEARCH (2017)
Effect of hyperthermic intrathoracic chemotherapy on the malignant pleural mesothelioma: a systematic review and meta-analysis
Zi-Yi Zhao et al.
ONCOTARGET (2017)
Functional expression of Programmed Death-Ligand 1 (B7-H1) by immune Cells and Tumor Cells
Rachel M. Gibbons Johnson et al.
FRONTIERS IN IMMUNOLOGY (2017)
Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma
Simone B. S. P. Terra et al.
ONCOIMMUNOLOGY (2017)
Oncolytic viral Therapy for Mesothelioma
Daniel F. Pease et al.
FRONTIERS IN ONCOLOGY (2017)
MiRNA-155 promotes proliferation by targeting caudal-type homeobox 1 (CDX1) in glioma cells
Lei Yang et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Checkmate 743: A phase 3 randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma.
Gerard Zalcman et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Evaluating the effect of immune cells on the outcome of patients with mesothelioma
Serena J. Chee et al.
BRITISH JOURNAL OF CANCER (2017)
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition
Gayathri Srinivasan et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Checkpoint Blockade in Lung Cancer and Mesothelioma
Lysanne A. Lievense et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2017)
Novel insights into mesothelioma biology and implications for therapy
Timothy A. Yap et al.
NATURE REVIEWS CANCER (2017)
INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors
Eric Angevin et al.
CANCER RESEARCH (2017)
First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers
Eric Angevin et al.
BRITISH JOURNAL OF CANCER (2017)
Extended Pleurectomy-Decortication-Based Treatment for Advanced Stage Epithelial Mesothelioma Yielding a Median Survival of Nearly Three Years
Joseph S. Friedberg et al.
ANNALS OF THORACIC SURGERY (2017)
PD-1 and PD-L1 antibodies in cancer: current status and future directions
Arjun Vasant Balar et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma
Robin Cornelissen et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2016)
A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors
J. C. Soria et al.
ANNALS OF ONCOLOGY (2016)
CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma
M. Betti et al.
CANCER LETTERS (2016)
Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy
Daniel H. Sterman et al.
CLINICAL CANCER RESEARCH (2016)
Possible new therapeutic agents for malignant pleural mesothelioma: anti-CD26 monoclonal antibody and naftopidil
Takashi Nakano et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2016)
Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges
Chrisann Kyi et al.
IMMUNOTHERAPY (2016)
Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma
Andreas Rimner et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
NCCN Guidelines® Insights Malignant Pleural Mesothelioma, Version 3.2016 Featured Updates to the NCCN Guidelines
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2016)
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma
Marc de Perrot et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2016)
A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes
Wieneke A. Buikhuisen et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles
Pascal Andujar et al.
JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART B-CRITICAL REVIEWS (2016)
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
Gerard Zalcman et al.
LANCET (2016)
Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial
Amelia O. Clive et al.
LANCET ONCOLOGY (2016)
Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1
Matthew Locke et al.
CELL REPORTS (2016)
Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (AR).
George R. Blumenschein et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
P. Baas et al.
ANNALS OF ONCOLOGY (2015)
Radical Radiation Therapy After Lung-Sparing Surgery for Malignant Pleural Mesothelioma: Survival, Pattern of Failure, and Prognostic Factors
Emilio Minatel et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)
Successful Combined Intratumoral Immunotherapy of Established Murine Mesotheliomas Requires B-Cell Involvement
Shruti Krishnan et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2015)
Loss of BAP1 function leads to EZH2-dependent transformation
Lindsay M. LaFave et al.
NATURE MEDICINE (2015)
FAK signaling in human cancer as a target for therapeutics
Brian Y. Lee et al.
PHARMACOLOGY & THERAPEUTICS (2015)
miR-29b attenuates tumorigenicity and stemness maintenance in human glioblastoma multiforme by directly targeting BCL2L2
Hyun Joo Chung et al.
ONCOTARGET (2015)
Early experience with intensity modulated proton therapy for lung-intact mesothelioma: A case series
Hubert Y. Pan et al.
PRACTICAL RADIATION ONCOLOGY (2015)
Extrapleural Pneumonectomy in the Treatment of Epithelioid Malignant Pleural Mesothelioma Novel Prognostic Implications of Combined N1 and N2 Nodal Involvement Based on Experience in 529 Patients
David J. Sugarbaker et al.
ANNALS OF SURGERY (2014)
Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma
Raffit Hassan et al.
CLINICAL CANCER RESEARCH (2014)
A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy
B. C. John Cho et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis
Aaron Scott Mansfield et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair
Helen Yu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
Prasad S. Adusumilli et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
Gregory L. Beatty et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Vaccination with WT1 mRNA-Electroporated Dendritic Cells: Report of Clinical Outcome in 66 Cancer Patients
Zwi N. Berneman et al.
BLOOD (2014)
Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma
G. Reid et al.
ANNALS OF ONCOLOGY (2013)
Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008
S. Jane Henley et al.
INTERNATIONAL JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH (2013)
Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy
Sophie Papa et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells
Petra C. Schuberth et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
Luana Calabro et al.
LANCET ONCOLOGY (2013)
Pleural Intensity-Modulated Radiotherapy for Malignant Pleural Mesothelioma
Kenneth E. Rosenzweig et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma
Anna K. Nowak et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma
Loic Lang-Lazdunski et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107)
Thierry Jahan et al.
LUNG CANCER (2012)
Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium
Nicholas P. Campbell et al.
LUNG CANCER (2012)
Cancer immunotherapy via dendritic cells
Karolina Palucka et al.
NATURE REVIEWS CANCER (2012)
A Trial of Intrapleural Adenoviral-mediated Interferon-α2b Gene Transfer for Malignant Pleural Mesothelioma
Daniel H. Sterman et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers
Mohamed H. Abdel-Rahman et al.
JOURNAL OF MEDICAL GENETICS (2011)
Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group
Scott A. Laurie et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma
Loic Lang-Lazdunski et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma SWOG S0509
Linda L. Garland et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
Tom Treasure et al.
LANCET ONCOLOGY (2011)
Germline BAP1 mutations predispose to malignant mesothelioma
Joseph R. Testa et al.
NATURE GENETICS (2011)
An In Vivo Platform for Tumor Biomarker Assessment
Elliot L. Servais et al.
PLOS ONE (2011)
CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection
Noriyuki Yamada et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor
Yangbing Zhao et al.
CANCER RESEARCH (2010)
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
A Phase II Study of Sorafenib in Malignant Mesothelioma Results of Cancer and Leukemia Group B 30307
Sarita Dubey et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Multicenter Phase II Trial of Neoadjuvant Pemetrexed Plus Cisplatin Followed by Extrapleural Pneumonectomy and Radiation for Malignant Pleural Mesothelioma
Lee M. Krug et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
miRiad roles for the miR-17-92 cluster in development and disease
Joshua T. Mendell
CELL (2008)
Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma
Masaki Anraku et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2008)
Trimodality treatment of malignant pleural mesothelioma
Hasan Fevzi Batirel et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors
Teruo Inamoto et al.
CLINICAL CANCER RESEARCH (2007)
Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics
Jennifer A. MacDiarmid et al.
CANCER CELL (2007)
Thalidomide in patients with malignant pleural mesothelioma
P Baas et al.
LUNG CANCER (2005)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
NJ Vogelzang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma
VW Rusch et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2001)
Localised spontaneous regression in mesothelioma - possible immunological mechanism
BWS Robinson et al.
LUNG CANCER (2001)
Share Paper
